During the past decade, remarkable progress has been made in the development of newer drugs to prevent and treat thromboembolic disorders, such as oral direct anti-Xa and anti-IIa antagonists, as well as oral antiplatelet ADP antagonists with rapid onset and offset. In addition, there has been concentrated effort aimed at identifying novel uses of traditional antithrombotic drugs, such as aspirin, heparin, and oral anticoagulants, as well as combinations of agents, such as more than one antiplatelet, antiplatelet with anticoagulant, antiplatelet with or without thrombolytic. Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition provides updates on various strategies in thrombosis, experimental models, and clinical and recent advances in the discovery and development of novel antithrombotics. As a volume in the highly successful Methods in Molecular Biology™ series, this collection provides the kind of detailed description and implementation advice that is crucial for getting optimal results. Easy to use and up to date, Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition is an ideal guide for researchers aiming for the future of this vital field, focusing on the prevention of thromboembolic disorders and the protection of the vascular endothelium.
